Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Total Non-Current Liabilities: 2010-2021

Historic Total Non-Current Liabilities for Neurocrine Biosciences (NBIX) over the last 10 years, with Sep 2021 value amounting to $663.0 million.

  • Neurocrine Biosciences' Total Non-Current Liabilities fell 4.47% to $663.0 million in Q3 2021 from the same period last year, while for Sep 2021 it was $663.0 million, marking a year-over-year decrease of 4.47%. This contributed to the annual value of $598.8 million for FY2020, which is 8.16% down from last year.
  • According to the latest figures from Q3 2021, Neurocrine Biosciences' Total Non-Current Liabilities is $663.0 million, which was up 2.28% from $648.2 million recorded in Q2 2021.
  • Over the past 5 years, Neurocrine Biosciences' Total Non-Current Liabilities peaked at $694.0 million during Q3 2020, and registered a low of $42.1 million during Q1 2017.
  • Its 3-year average for Total Non-Current Liabilities is $624.0 million, with a median of $640.0 million in 2020.
  • Over the last 5 years, Neurocrine Biosciences' Total Non-Current Liabilities had its largest YoY gain of 796.41% in 2017, and its largest YoY loss of 8.76% in 2017.
  • Neurocrine Biosciences' Total Non-Current Liabilities (Quarterly) stood at $424.9 million in 2017, then reached $476.7 million in 2018, then skyrocketed by 36.77% to $652.0 million in 2019, then fell by 8.16% to $598.8 million in 2020, then declined by 4.47% to $663.0 million in 2021.
  • Its Total Non-Current Liabilities was $663.0 million in Q3 2021, compared to $648.2 million in Q2 2021 and $619.5 million in Q1 2021.